Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premedication for Less Invasive Surfactant Administration (LISA-Med)
2025-520492-10-00Phase 4Authorised
- Sponsor
- Pohjois-Pohjanmaan hyvinvointialue
- Start
- Jan 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fentanyl and esketamine in respiratory distress syndrome (RDS) (2 arms), sponsored by Pohjois-Pohjanmaan hyvinvointialue. Primary endpoint: Any adverse event during or shortly after LISA with premedication. Planned start Jan 2025; status: authorised.
02
Drugs
fentanylesketamine
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2025-520492-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520492-10-00.